PCSK9 Race Heats Up as Amgen Candidate Enters Phase III

Drug Industry Daily
A A
Positive results from the first long-term trial of evolocumab, Amgen’s next-generation heart drug, are heating up the race to develop the emerging class of drugs known as PCSK9 inhibitors.

To View This Article:

Login

Subscribe To Drug Industry Daily